Stocks that are likely to record significant movement on bourses today
Stocks that are likely to record significant movement on bourses today

Stocks that are likely to record significant movement on bourses today

Karan Dsij Article rating: 4.2

Sterlite Technologies: The company has made a number of key leadership appointments to expand its capabilities to offer end-to-end advanced solutions for digital networks, and drive its next phase of growth.

Can lingering concerns about rising Coronavirus cases & fear of fresh lockdown imposition put full stop to bull express?
Can lingering concerns about rising Coronavirus cases & fear of fresh lockdown imposition put full stop to bull express?

Can lingering concerns about rising Coronavirus cases & fear of fresh lockdown imposition put full stop to bull express?

Karan Dsij Article rating: 5.0

Even though the markets ended in green on Monday, volatility was the hallmark of the session as India VIX rose by 3.25 to 19.40. Further, multiple indecisive candle formations on the daily chart signalled that the dominant bulls are witnessing a slowdown in their pace of ascending.

Nifty trend for Tuesday
Nifty trend for Tuesday

Nifty trend for Tuesday

Karan Dsij Article rating: 4.5

Overall, Nifty seems to move slowly and gradually in the northward directions but with the formation of multiple indecisive candles in the last couple of trading sessions, it clearly indicates that the momentum is dwindling and if the indecisive bars get a confirmation (by closing below the prior bar low), the bears would smell the blood.

Sensex, Nifty at record highs; Burger King gains 131 per cent on listing debut, ONGC jumps 5 per cent, Adani Green declines
Sensex, Nifty at record highs; Burger King gains 131 per cent on listing debut, ONGC jumps 5 per cent, Adani Green declines

Sensex, Nifty at record highs; Burger King gains 131 per cent on listing debut, ONGC jumps 5 per cent, Adani Green declines

Geyatee Deshpande Article rating: 3.8

Markets ended close to record highs as Sensex gained by 154.45 points or by 0.34 per cent to settle at 46,253.46 levels while Nifty rose by 44.30 points or 0.33 per cent to close at 13,558.15 levels.

Cipla rises more than 4 per cent after settling over cancer drug Revlimid; earnings likely to boost
Cipla rises more than 4 per cent after settling over cancer drug Revlimid; earnings likely to boost

Cipla rises more than 4 per cent after settling over cancer drug Revlimid; earnings likely to boost

Deepti Shidore Article rating: 4.0

Cipla has settled its patent litigation with Celgene over the blockbuster cancer drug Revlimid. Celgene Corporation, a subsidiary of Bristol Myers Squibb, has agreed to provide Cipla with a licence to Celgene’s required patents. Cipla can then sell or manufacture certain volume-limited amounts of generic Lenalidomide in the United States sometime after March 2022.

RSS
First19011902190319041906190819091910Last

DALAL STREET INVESTMENT JOURNAL - DEMOCRATIZING WEALTH CREATION

Principal Officer: Mr. Shashikant Singh,
Email: principalofficer@dsij.in
Tel: (+91)-20-66663800

Compliance Officer: Mr. Rajesh Padode
Email: complianceofficer@dsij.in
Tel: (+91)-20-66663800

Grievance Officer: Mr. Rajesh Padode
Email: service@dsij.in
Tel: (+91)-20-66663800

Corresponding SEBI regional/local office address- SEBI Bhavan BKC, Plot No.C4-A, 'G' Block, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra.
Tel: +91-22-26449000 / 40459000 | Fax : +91-22-26449019-22 / 40459019-22 | E-mail : sebi@sebi.gov.in | Toll Free Investor Helpline: 1800 22 7575 | SEBI SCORES | SMARTODR